ライフサイエンスコーパス: paricalcitol

1 VDR-independent anti-inflammatory effect of paricalcitol.

2 accompanied these renoprotective effects of paricalcitol.

3 roxylase, resulting in increased activity of paricalcitol.

4 secondary hyperparathyroidism received oral paricalcitol 1 mug/d for 3 months, and 8 patients matche

5 conclusion, 52 weeks of treatment with oral paricalcitol (1 mug one time daily) significantly improv

6 ere randomly assigned to receive either oral paricalcitol (1 mug) one time daily (n=30) or matching p

7 ompared the effect of 6-month treatment with paricalcitol (1 mug/d for 3 months and then uptitrated t

8 atment of the diabetic mice with losartan or paricalcitol (19-nor-1,25-dihydroxyvitamin D(2), an acti

9 This study investigated the effects of paricalcitol (19-nor-1,25-hydroxy-vitamin D(2)), a synth

10 Paricalcitol (19-nor-1alpha-25-dihydroxyvitamin D2), a n

11 ril (30 mg/L in drinking water; E), uremic + paricalcitol (19-nor; 0.8 microg/kg, three times a week)

12 cipients were randomized 1:1 to receive oral paricalcitol, 2 mug per day, for the first year posttran

13 pants were randomly assigned to receive oral paricalcitol, 2 mug/d (n =115), or matching placebo (n =

14 Of 40 patients receiving paricalcitol, 27 (68%) had at least a 30% decrease in se

15 alysis who started to receive treatment with paricalcitol (29,021 patients) or calcitriol (38,378 pat

16 Paricalcitol, a new vitamin D analogue, appears to lesse

17 Paricalcitol, a selective vitamin D receptor activator,

18 In vitro, paricalcitol abolished TGF-beta1-mediated E-cadherin sup

19 omatin immunoprecipitation assay showed that paricalcitol abolished the binding of p65 to its cognate

20 TRAF3 interaction mediated the mechanisms of paricalcitol action.TRAF3 overexpression by CRISPR/Cas9

21 Paricalcitol administration resulted in a median percent

22 Paricalcitol administration to renal transplant patients

23 S induction depended on NF-kappaB signaling, paricalcitol affected neither TNF-alpha-mediated IkappaB

24 It is interesting that paricalcitol almost completely suppressed renal inductio

25 Administration of paricalcitol also ameliorated established proteinuria.

26 Paricalcitol also inhibited expression of proinflammator

27 ARalpha in PR9 cells, and the combination of paricalcitol and As2O3 enhanced their monocytic differen

28 In summary, the combination of paricalcitol and As2O3 potently decreased growth and ind

29 ant difference in adverse events between the paricalcitol and placebo-treated groups.

30 ns retrieved, six studies (four studies with paricalcitol and two studies with calcitriol) providing

31 -ray absorption, significantly improved with paricalcitol at 6 months (P<0.05 for both densities).

32 obably by increasing intracellular levels of paricalcitol by decreasing the function of the mitochond

33 owever, combined treatment with losartan and paricalcitol completely prevented albuminuria, restored

34 sues, we tested whether the vitamin D analog paricalcitol could ameliorate podocyte injury, proteinur

35 Paricalcitol decreases intact parathyroid hormone and th

36 ata suggest the anti-inflammatory actions of paricalcitol depend on TRAF3 modulation and subsequent i

37 Forty-eight week therapy with paricalcitol did not alter left ventricular mass index o

38 In vivo, paricalcitol did not block NF-kappaB nuclear translocati

39 , PBMCs from patients with ESKD treated with paricalcitol did not exhibit these features.

40 hree times a week), and uremic + enalapril + paricalcitol (E + 19-nor).

41 In this study, we explored if paricalcitol enhanced anticancer effects of other clinic

42 roteinuric rats were treated with vehicle or paricalcitol for 6 consecutive weeks.

43 oid hormone levels significantly declined on paricalcitol from 115.6 (94.8-152.0) to 63.3 (52.0-79.7)

44 s of hypercalcemia were more frequent in the paricalcitol group compared with the placebo group.

45 olic lateral mitral annular tissue velocity (paricalcitol group, -0.01 cm/s [95% CI, -0.63 to 0.60 cm

46 dex did not differ between treatment groups (paricalcitol group, 0.34 g/m(2.7) [95% CI, -0.14 to 0.83

47 y 6.7 and 11.9 percent, respectively, in the paricalcitol group, as compared with 8.2 and 13.9 percen

48 emic vitamin D analogue (19-nor-1,25(OH)2D2; paricalcitol) had anticancer activity.

49 In vitro, paricalcitol induced a physical interaction between the

50 Paricalcitol induced monocytic differentiation of U937 A

51 ng-term studies are needed to assess whether paricalcitol-induced increase in KLOTHO gene expression

52 ic blockade of Wnt/beta-catenin signaling by paricalcitol inhibited MMP-7 expression in diseased kidn

53 a human proximal tubular cell line (HKC-8), paricalcitol inhibited RANTES mRNA and protein expressio

54 In a preclinical model of kidney injury, paricalcitol inhibited renal NF-kappaB2 activation and d

55 Furthermore, paricalcitol inhibited the TGF-beta1-mediated Snail indu

56 These results suggest that paricalcitol inhibits renal inflammatory infiltration an

57 A total of 78 patients (40 Paricalcitol injection, 38 placebo) achieved treatment p

58 These studies suggest that paricalcitol is able to ameliorate renal interstitial fi

59 Oral paricalcitol is effective in decreasing posttransplant h

60 epithelial cells, accompanied renal injury; paricalcitol largely abolished this induction of renal b

61 Paricalcitol largely preserved E-cadherin and reduced al

62 linically relevant dosages of calcitriol and paricalcitol may protect against CKD-stimulated vascular

63 effects of the VDR activators calcitriol and paricalcitol on aortic calcification in a mouse model of

64 -concept study aimed to assess the effect of paricalcitol on fibroblast growth factor-23/KLOTHO axis

65 We examined the effect of oral paricalcitol on posttransplant secondary hyperparathyroi

66 e effect of the synthetic vitamin D analogue paricalcitol on renal inflammation was investigated in a

67 After a 4-wk washout, paricalcitol or placebo was administered intravenously t

68 24-hour proteinuria level decreased only on paricalcitol (P<0.05).

69 effects of the vitamin D receptor activator paricalcitol (PARI) and dietary sodium restriction on re

70 Here, we investigated whether paricalcitol (PC, 19-nor-1,25(OH)(2)D(2)), an activated

71 Compared with vehicle-treated controls, paricalcitol preserved expression of nephrin, podocin, a

72 that treatment with active vitamin D analog paricalcitol prevented mouse body weight loss and allevi

73 In VDR knockout mice with renal injury, paricalcitol prevented TRAF3 downregulation and NF-kappa

74 In summary, these findings suggest that paricalcitol prevents podocyte dysfunction, proteinuria,

75 O3 increased the transcriptional activity of paricalcitol probably by increasing intracellular levels

76 Paricalcitol reduced infiltration of T cells and macroph

77 Treatment with paricalcitol reduced parathyroid hormone levels within 4

78 These studies demonstrate that paricalcitol safely and effectively suppresses iPTH leve

79 pared with vehicle-treated proteinuric rats, paricalcitol showed markedly reduced renal lymphangiogen

80 Compared with vehicle controls, paricalcitol significantly attenuated renal interstitial

81 adynamic bone disorder; both calcitriol and paricalcitol stimulated osteoblast surfaces and rates of

82 Overall, 6-month paricalcitol supplementation reduced parathyroid hormone

83 In addition, paricalcitol suppressed renal TGF-beta1 and its type I r

84 The dose of paricalcitol that decreased iPTH by at least 30% became

85 atients who received 12 wk of treatment with paricalcitol, the levels of iPTH decreased significantly

86 d assessed changes after cholecalciferol and paricalcitol therapies in both vitamin D-responsive prot

87 ine phosphatase and osteocalcin decreased on paricalcitol therapy only and significantly differed bet

88 Two subjects required decreasing the dose of paricalcitol to 1 mug daily.

89 ith 64 percent among those who switched from paricalcitol to calcitriol (P=0.04).

90 Intact parathyroid hormone decreased in paricalcitol-treated patients (P < 0.0001).

91 lood mononuclear cells increased by 45.7% in paricalcitol-treated patients (P < 0.01), without change

92 Paricalcitol-treated patients showed a decrease in the m

93 confidence interval, 10 to 21 percent) among paricalcitol-treated patients than among calcitriol-trea

94 eving target serum iPTH levels in any of the paricalcitol-treated patients.

95 nge in controls, but it increased by 177% in paricalcitol-treated subjects (P < 0.0001).

96 One-year posttransplant, 29% of paricalcitol-treated subjects had hyperparathyroidism co

97 miR-27a/b levels in the oral epithelium from paricalcitol-treated, vitamin D deficient or VDR knockou

98 Paricalcitol treatment resulted in a significant reducti

99 However, paricalcitol treatment significantly reduced intact para

100 At the molecular level, paricalcitol treatment suppressed the induction of fibro

101 Paricalcitol treatment suppressed the induction of these

102 p65 formed a complex in tubular cells after paricalcitol treatment, which inhibited the ability of p

103 le range], -2.59 [-6.13 to 0.32] g/m(2) with paricalcitol versus -4.85 [-9.89 to 1.10] g/m(2) with pl

104 The mortality rate among patients receiving paricalcitol was 3417 per 19,031 person-years (0.180 per

105 ong patients who switched from calcitriol to paricalcitol was 73 percent, as compared with 64 percent

106 Paricalcitol was discontinued in four patients due to hy

107 ptor-associated factor 3 (TRAF3) by the VDRA paricalcitol was studied in PBMCs from patients with ESK

108 Paricalcitol was well tolerated.

109 econdary hyperparathyroidism, calcitriol and paricalcitol were protective against aortic calcificatio

110 Paricalcitol, when combined with As2O3, showed a markedl

111 Patients who receive paricalcitol while undergoing long-term hemodialysis app

112 ion of the active pharmaceutical ingredient, paricalcitol (Zemplar).